

Supplementary material

Archives of Gynecology and Obstetrics

Reasons for low cervical cancer survival in new-accession European Union countries. A EUROCORE-5 study.

Magdalena Bielska-Lasota, Silvia Rossi, Michalina Krzyżak, Annemie Haelens, Augius Domenic, Roberta De Angelis, Adam Maciejczyk, Miguel Rodríguez-Barranco, Vesna Zadnik, Pamela Minicozzi, and the EUROCORE-5 Working Group

Corresponding author

Pamela Minicozzi, PhD

Cancer Survival Group

Department of Non-Communicable Disease Epidemiology

London School of Hygiene and Tropical Medicine,

Keppel St, London WC1E 7HT, UK

Tel: +44 20 7927 2203

E-mail: pamela.minicozzi@lshtm.ac.uk

Supplementary Table 1. List of the 85 population-based cancer registries (CRs) included in the morphology (A) and stage (B) analyses, by European region and country

Region/Country	Cancer registry	Analysis by		
		Morphology	Stage at diagnosis	
Northern Europe				
Finland	Finland	A		
Iceland	Iceland	A		
Norway	Norway	A	B	
Sweden	Sweden	A		
Ireland and UK				
Ireland	Ireland	A		
United Kingdom	England	A		
	Northern Ireland	A		
	Scotland	A		
	Wales	A		
Central Europe				
Austria	Austria	A	B	
Belgium	Flanders	A		
France	Bas Rhin	A		
	Calvados	A		
	Doubs	A		
	Hérault	A		
	Isère	A		
	Loire Atlantique	A		
	Manche	A		
	Somme	A		
	Tarn	A		
	Germany	Brandenburg	A	
		Bremen	A	
		Hamburg	A	
		Mecklenburg-West	A	
		Pomerania	A	
Munich		A		
North Rhine Westphalia		A		
Saarland		A		
Switzerland	Saxony	A		
	Basel	A		
	Geneva	A		
	Grisons	A	B	
	St. Gallen	A		
	Ticino	A		
	Valais	A		
The Netherlands	The Netherlands	A		
Southern Europe				
Croatia	Croatia	A		
Italy	Alto Adige	A		
	Biella	A		
	Catanzaro	A		
	Ferrara	A		
	Firenze-Prato	A		
	Friuli Venezia Giulia	A		
	Genova	A		
	Latina	A		
	Mantova	A		
	Milano	A		
	Modena	A		
	Napoli	A		
	Nuoro	A		

	Palermo	A	
	Parma	A	B
	Ragusa	A	
	Reggio Emilia	A	
	Romagna	A	
	Salerno	A	
	Sassari	A	
	Siracusa	A	
	Sondrio	A	
	Torino	A	
	Trapani	A	
	Trento	A	
	Umbria	A	
	Varese	A	
	Veneto	A	
Malta	Malta	A	
Portugal	Açores	A	
	Northern Portugal	A	
	Southern Portugal	A	
Slovenia	Slovenia	A	B
Spain	Basque Country	A	
	Cuenca	A	
	Girona	A	
	Granada	A	
	Murcia	A	
	Navarra	A	B
	Tarragona	A	
Eastern Europe			
Bulgaria	Bulgaria	A	
Czech Republic	Czech Republic	A	
Estonia	Estonia	A	
Latvia	Latvia	A	
Lithuania	Lithuania	A	
Poland	Cracow	A	
	Kielce	A	
	Lower Silesia	A	B
Slovakia	Slovakia	A	B
Total CRs		85	8

Supplementary Table 2. Definition of the three morphological subgroups analysed for women diagnosed with cervical cancer in 2000-2007 in 28 European countries

Morphological subgroup	Morphological ICDO-3^a codes
Squamous tumour	8051, 8052, 8070, 8071, 8072, 8076, 8082, 8083
<i>Microinvasive squamous cell carcinoma (MSCC)</i>	8076
Glandular tumours	8140, 8144, 8262, 8310, 8380, 8384, 8441, 8480, 8482, 8490
Other malignancies ^b	8000-8005, 8010-8013, 8015, 8020-8022, 8030-8033, 8040-8042, 8044-8046, 8050, 8073-8075, 8078, 8084, 8098, 8120, 8123-8124, 8130, 8141, 8143, 8147, 8190, 8200, 8201, 8210-8211, 8230, 8240-8241, 8245-8246, 8255, 8260-8261, 8263, 8320, 8323, 8382-8383, 8410, 8430, 8440, 8450, 8460-8461, 8470, 8472, 8481, 8500, 8503, 8510, 8550, 8560, 8570, 8572, 8574-8575, 8720, 8730, 8746, 8770, 8772, 8800-8803, 8805, 8810, 8830, 8850, 8852, 8890-8891, 8895-8896, 8900-8901, 8910, 8920, 8930, 8931, 8933, 8935, 8950-8951, 8980, 8940, 8990, 9071, 9100, 9105, 9110, 9364, 9473, 9540, 9571, 9581

^a ICDO-3, third revision of the International Classification of Diseases for Oncology; ^b Including non-pertinent locations

Supplementary Table 3. Proportion (%) of microinvasive squamous cell carcinoma (MSCC) relative to the number of squamous cervical cancers (No.) diagnosed in 2000-2007, overall and by European region

Age at diagnosis (years)	All cases		<i>New MS</i> ^a		<i>Other countries</i> ^a		Northern Europe		Ireland and United Kingdom		Central Europe		Southern Europe		Eastern Europe	
	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%	No.	%
15-29	3,837	22.0	1,044	17.9	2,793	23.6	292	20.2	1,761	25.7	580	21.0	277	19.1	927	17.3
30-44	24,575	13.9	8,423	10.2	16,152	15.9	1,747	17.2	6,488	19.2	5,816	13.7	3,162	13.2	7,362	9.0
45-54	16,354	7.0	7,281	5.5	9,073	8.1	883	9.5	2,811	10.0	3,684	7.1	2,497	7.2	6,479	5.1
55-64	11,828	3.8	5,100	3.0	6,728	4.5	753	2.9	2,111	6.4	2,475	4.2	1,880	3.3	4,609	2.8
65-74	9,270	2.4	3,435	2.5	5,835	2.4	577	2.4	1,758	1.6	2,270	3.0	1,670	2.8	2,995	2.2
≥75	8,649	1.2	2,071	1.3	6,578	1.1	905	1.5	2,201	0.8	2,291	1.5	1,469	0.7	1,783	1.4

^a MS, Member States. The *new MS* corresponded to the 10 countries (Bulgaria, Croatia, Czech Republic, Estonia, Latvia, Lithuania, Malta, Poland, Slovakia, Slovenia) that joined the European Union in 2004 or later; the *Other countries* corresponded to the remaining 18 countries participating to the EURO CARE-5 study (Finland, Iceland, Norway, Sweden, Ireland, UK-England, UK-Northern Ireland, UK-Scotland, UK-Wales, Austria, Belgium, France, Germany, Switzerland, The Netherlands, Italy, Portugal, Spain).

Supplementary Table 4. Age distribution (No, %) for all cervical cancers and squamous tumours only, diagnosed in 2000-2007 in the 8 countries with available information on stage at diagnosis, overall, by European region, and stage at diagnosis

	Age at diagnosis (years)	All cases ^a		Northern Europe		Central Europe		Southern Europe		Eastern Europe		Squamous tumours			
												All cases ^b		Excluding MSCC	
												No.	%	No.	%
All cases	15-29	552	4.0	138	5.9	163	4.3	73	4.2	178	2.9	391	4.0	307	3.5
	30-44	4,280	30.7	855	36.6	1,108	29.1	622	35.9	1,695	28.0	3,229	33.1	2,693	30.5
	45-54	3,527	25.3	461	19.7	779	20.5	430	24.8	1,857	30.7	2,477	25.4	2,268	25.7
	55-64	2,316	16.6	353	15.1	635	16.7	251	14.5	1,077	17.8	1,583	16.2	1,520	17.2
	65-74	1,632	11.7	217	9.3	494	13.0	182	10.5	739	12.2	1,044	10.7	1,013	11.5
	≥75	1,630	11.7	315	13.5	629	16.5	173	10.0	513	8.5	1,039	10.6	1,027	11.6
Local stage	15-29	375	5.1	81	7.2	124	5.9	63	6.0	107	3.5	284	5.2	200	4.4
	30-44	2,854	38.9	546	48.7	789	37.2	481	45.6	1,038	34.1	2,236	41.3	1723	38.1
	45-54	1,852	25.2	206	18.4	441	20.8	259	24.5	946	31.1	1,328	24.5	1125	24.9
	55-64	1,070	14.6	135	12.0	301	14.2	128	12.1	506	16.6	753	13.9	693	15.3
	65-74	695	9.5	81	7.2	237	11.2	76	7.2	301	9.9	466	8.6	437	9.7
	≥75	497	6.8	72	6.4	227	10.7	49	4.6	149	4.9	349	6.4	341	7.5
Regional stage	15-29	75	2.2	15	4.0	20	2.6	9	1.6	31	1.8				
	30-44	791	22.9	96	25.4	160	20.4	121	21.7	414	23.8				
	45-54	913	26.4	80	21.2	175	22.4	147	26.3	511	29.4				
	55-64	663	19.2	78	20.6	159	20.3	101	18.1	325	18.7				
	65-74	488	14.1	36	9.5	120	15.3	86	15.4	246	14.2				
	≥75	526	15.2	73	19.3	149	19.0	94	16.9	210	12.1				
Metastatic stage	15-29	13	1.3	6	2.8	2	0.8	0	0	5	1.1				
	30-44	142	14.3	35	16.4	38	14.4	10	14.7	59	13.1				
	45-54	245	24.6	42	19.6	48	18.2	18	26.5	137	30.5				
	55-64	238	23.9	45	21.0	75	28.4	18	26.5	100	22.3				
	65-74	160	16.1	32	15.0	41	15.5	12	17.7	75	16.7				
	≥75	197	19.8	54	25.2	60	22.7	10	14.7	73	16.3				
Unknown stage	15-29	89	4.2	36	5.8	17	2.7	1	2.0	35	4.2				
	30-44	493	23	178	28.4	121	18.9	10	20.4	184	22.3				
	45-54	517	24.1	133	21.3	115	17.9	6	12.2	263	31.8				
	55-64	345	16.1	95	15.2	100	15.6	4	8.2	146	17.7				
	65-74	289	13.5	68	10.9	96	15.0	8	16.3	117	14.2				
	≥75	410	19.1	116	18.5	193	30.1	20	40.8	81	9.8				

^a Northern Europe represented by Norway; Central Europe by Austria and the Swiss cancer registry (CR) of Grisons, Southern Europe by the Italian CR of Parma, the Spanish CR of Navarra, and Slovenia; and Eastern Europe by the Polish CR of Lower Silesia and Slovakia; ^bIncluding microinvasive squamous cell carcinoma (MSCC)